Covid Vaccines Have Paved the Way for Cancer Vaccines

Thus, the UK government has signed two partnerships: a 10,000 patient with a bionatek provides access to personalized cancer treatment by 2030 and provides 10 years of investment with a modern and technology center with the ability to produce up to 250 million vaccine. The stars were aligned.

During the epidemic, the UK was opening a clinical trial within a few weeks. However, it took years to complete the clinical trial. What has changed?

It was really interesting, because for many years we believe that research is inherently slow. It takes 20 years to get drugs in the market. Unfortunately, most cancer patients die when a drug comes to market. We have shown the world that if you modernize your process, run parts of the process in parallel and use digital tools, it can be done in one year.

Of course, opening a clinical trial during the epidemic is not the same as a clinical trial for cancer. But in the early stages you had a breakthrough moment for the cancer vaccine project.

There was a trial run by BionTech, known as BNT 122, on those with high-risky bowel cancer, which was not well recruited around the world. So when we announce the cancer vaccine launch pad, the UK’s cancer community took that opportunity. We opened the trial at Birmingham University Hospital, which was the most surprising thing for me, because it was not a top cancer vaccine Studies Center.

We need to get 10,000 patients listed in the exam and we’ve arrived there in three months. It was quite amazing. It just goes to show it because we are a single healthcare system, we can make it faster than any other country.

Dominos began to fall very quickly behind that success: we opened a head and neck cancer in Liverpool, a esophageal and gastric cancer trial in Dundee and lung cancer trial in London. We have begun to create a community that all of them were pressing the cancer vaccine trials to turn on as soon as possible.

Several MRNA-based cancer vaccines are internationally in the late-level clinical trials, and the UK is currently running 15 cancer-vaccine trials. When do we see the first approved MRNA cancer vaccine?

We have a test to stop the skin cancer returning after you cut it. It has been completed now. We have recruited the extra again, just like every trial we ran, and this trial ended a year before the trial schedule. It is not fully heard in cancer trials because they are usually more long.

What happens now is, within the next six to 12 months we will observe the people of the trial and if there is a difference between the cancer vaccine and those who are not. We expect the results at the end of the year or at the beginning of 2026. If this is successful, we will discover the first approved personalized MRNA vaccine in just five years of MRNA vaccine for Covid. It’s quite impressive.

Listen to Lenard Lee speak at Cable health March 18 in Kings Plays in London. To get tickets Health. WIRED.comThe